×







We sell 100% Genuine & New Books only!

Cervix Cancer 1st Editon 2011 Softbound at Meripustak

Cervix Cancer 1st Editon 2011 Softbound by Earl A. Surwit, David Alberts, Springer

Books from same Author: Earl A. Surwit, David Alberts

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Price: ₹ 12944.00/- [ 15.00% off ]

    Seller Price: ₹ 11002.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Earl A. Surwit, David Alberts
    PublisherSpringer
    Edition1st Editon
    ISBN9781461292074
    Pages208
    BindingSoftbound
    LanguageEnglish
    Publish YearSeptember 2011

    Description

    Springer Cervix Cancer 1st Editon 2011 Softbound by Earl A. Surwit, David Alberts

    Cytological screening for the identification of intraepithelial neoplasia of the cervix as a precursor lesion for cervical cancer has been well established as an effective means for decreasing the incidence of invasive carcinoma. Despite these screening efforts, carcinoma of the cervix remains one of the more common malignancies in women and it is the leading cause of cancer death in many countries in the western hemisphere. It is estimated that in 1986 there will still be 14,000 new cases of invasive cancer, with 6,800 deaths in the United States alone. Unfortunately, many of these patients present with advanced disease, posing difficult management problems for the clinician responsible for their care. The treatment of early stage invasive carcinoma of the cervix (lesions confined to the cervix and vagina) remains either radical surgery, radical radiation therapy or a combination thereof This approach is extraordinarily effective in the vast majority of patients. However, there remains a subset of patients with early stage disease that are at high risk for recurrence. Dr Kjorstad (Chapter 2) has identified adenocarcinomas and adenosqua­ mous carcinomas as having a particularly poor prognosis. In addition, patients with more than three positive lymph nodes or with involvement of lymph nodes outside of the pelvis have a very poor prognosis. He has iden­ tified the CEA as a potentially predictive marker for these patients with poor prognosis, especially in patients with adenocarcinomas. 1. Cervical dysplasia.- 2. The management of the high risk patient with early invasive carcinoma of the cervix.- 3. Cytosolic estrogen and progesterone receptors in primary cervical carcinoma.- 4. Surgical staging of cervical cancer.- 5. Pre-operative radiotherapy for carcinoma of the cervix.- 6. Radical hysterectomy and pelvic lymphadenectomy.- 7. Treatment of locally advanced cancer of the cervix with interstitial parametrial implants.- 8. Hydroxyurea and radiation therapy in the treatment of carcinoma of the cervix.- 9. Single agent chemotherapy in carcinoma of the cervix.- 10. Combination chemotherapy of advanced cervix cancer.- 11. Primary chemotherapy for high-risk recurrence cervix cancer.- 12. Human tumor clonogenic assay studies of cervical cancer.



    Book Successfully Added To Your Cart